CTI BIOPHARMA CORP. (NASDAQ:CTIC) Files An 8-K Financial Statements and Exhibits
Item 9.01
Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit |
Description |
|
99.1 |
Press Release dated December 28, 2018
|
CTI BIOPHARMA CORP Exhibit
EX-1 2 ctic-pac203completionofenr.htm EXHIBIT 1 Exhibit CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib- Optimal dose determination from the PAC203 study expected in mid-2019 with topline data expected in the third quarter of 2019 -SEATTLE,…
To view the full exhibit click here
About CTI BIOPHARMA CORP. (NASDAQ:CTIC)
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
